Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 46

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Dec 14, 2015; 21(46): 13087-13094
Published online Dec 14, 2015. doi: 10.3748/wjg.v21.i46.13087

Table 2 Risk factors of liver cancer

ALT: Alanine transaminase; CHB: Chronic hepatitis B; LC: Liver cirrhosis; HBeAg: Hepatitis B e antigen.

Citation: Su MH, Lu AL, Li SH, Zhong SH, Wang BJ, Wu XL, Mo YY, Liang P, Liu ZH, Xie R, He LX, Fu WD, Jiang JN. Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study. World J Gastroenterol 2015; 21(46): 13087-13094
URL: https://www.wjgnet.com/1007-9327/full/v21/i46/13087.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i46.13087

Su MH, Lu AL, Li SH, Zhong SH, Wang BJ, Wu XL, Mo YY, Liang P, Liu ZH, Xie R, He LX, Fu WD, Jiang JN. Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study. World J Gastroenterol 2015; 21(46): 13087-13094 [PMID: 26673249 DOI: 10.3748/wjg.v21.i46.13087]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.